As of 2026-09-12, the EV/EBITDA ratio of Prometheus Biosciences Inc (RXDX) is -58.45. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Prometheus's latest enterprise value is 9,445.47 mil USD. Prometheus's TTM EBITDA according to its financial statements is -161.61 mil USD. Dividing these 2 quantities gives us the above Prometheus EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 15.3x - 16.3x | 16.0x |
| Forward P/E multiples | 17.3x - 20.2x | 18.8x |
| Fair Price | (56.04) - (52.72) | (56.53) |
| Upside | -128.0% - -126.4% | -128.3% |
| Date | EV/EBITDA |